China-Based Genequantum Healthcare (Gq) And Wuxi Xdc, A Leading Global Contract Research, Development And Manufacturing Organisation (Crdmo), Have Entered Into A Strategic Collaboration For Conjugation Technology Licensing And Antibody Drug Conjugate (Adc) Drug Development.According To The Collaboration Agreements, Wuxi Xdc Will Actively Promote Genequantum'S Proprietary Ildc (Intelligent Ligase-Dependent Conjugation) And Igdc (Intelligent Glycotransferase-Dependent Conjugation) Platforms Around The Globe To Empower Innovative Bioconjugate Development And The Commercial Production For Drug Developers.Genequantum Will Also Develop Multiple Adc Drugs Through Collaboration With Wuxi Xdc, And Foresee Accelerated Product Commercialization Based On Wuxi Xdc'S Leading Adc Production Platform And Integrated Cmc Capability.Dr Jimmy Lee, Ceo Of Wuxi Xdc, Said, "New And Innovative Ideas And Technologies Have Emerged In The Field Of Bioconjugate Drugs Represented By Adc, Which Has Become A Hot Spot Of Investment And Drug Development."
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!